Next Meetings

October 25, 2018 10am-4pm PT

California Endowment Oakland Conference Center
2000 Franklin St.
Oakland, CA 94612

CTAF will convene to review ICER's assessment of therapies for hereditary angioedema.

Register

Opioid Use Disorder

New England CEPAC
November 8, 2018 10am - 4pm ET

Newton Marriott
2345 Commonwealth Avenue
Newton, MA 02466

The New England CEPAC will convene to review evidence on medications for addiction treatment in opioid use disorder.

Register

Asthma

Midwest CEPAC
November 29, 2018 10am-4pm CT

Hilton St. Louis Frontenac
1335 S Lindbergh Boulevard
St. Louis, MO 63131


February 21, 2019 10am-4pm PT

Preservation Park (Nile Hall)
668 13th Street, Oakland, CA 94612
Oakland CA, 94612

CTAF will convene to review ICER's assessment of canakinumab for atherosclerosis.


Spinal Muscular Atrophy

New England CEPAC
March 7, 2019 10am-4pm ET

Omni Parker House
60 School Street
Boston, MA 02108

The New England CEPAC will convene to deliberate and vote on ICER's report on treatments for SMA.


May 23, 2019 9am- 5pm CT

Hyatt Regency O’Hare
9300 Bryn Mawr Avenue
Rosemont, IL 60018

The Midwest CEPAC will convene to review evidence on esketamine as a therapy for treatment-resistant depression. The Council will also review a report on siponimod for treatment of secondary progressive MS during this meeting.


Multiple Sclerosis

Midwest CEPAC
May 23, 2019 9am-5pm CT

Hyatt Regency O’Hare
9300 Bryn Mawr Avenue
Rosemont, IL 60018

The Midwest CEPAC will convene to review ICER's assessment of siponimod (Novartis) for secondary progressive multiple sclerosis.


past Meetings

Sep 2018
Midwest CEPAC

Amyloidosis

The Midwest CEPAC deliberated and voted on ICER's report on treatments for hereditary transthyretin-related (hATTR) amyloidosis, a rare genetic condition characterized by nerve, heart, and eye damage that is currently treated through supportive measures alone. The Council also reviewd a report on therapies for prostate cancer during this meeting.